Oral contraceptive use and abnormal glucose regulation in Swedish middle aged women

Diabetes Research and Clinical Practice

Volumn 92, Issue 2, 2011, Pages 288-292

  Deleskog, A ^a,b   Hilding, A ^a   Ostenson C G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Merck Sharp Dohme (Sweden)   (Sweden)

Author keywords

Impaired fasting glucose; Impaired glucose tolerance; Oral contraceptives; Type 2 diabetes

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; PHYSICAL PERFORMANCE; POPULATION RESEARCH; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; SWEDEN;

ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HUMANS; MIDDLE AGED; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79955795583     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.02.014     Document Type: Article

References (26)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Lyssenko V., Jonsson A., Almgren P., Pulizzi N., Isomaa B., Tuomi T., et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008, 359:2220-2232.
3. Hamman R.F. Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992, 8:287-338.
4. Fagard R.H., Nilsson P.M. Smoking and diabetes - the double health hazard!. Prim Care Diabetes 2009, 3:205-209.
5. Baliunas D.O., Taylor B.J., Irving H., Roerecke M., Patra J., Mohapatra S., et al. Alcohol as a risk factor for type 2 diabetes: a systemic review and meta-analysis. Diabetes Care 2009, 32:2123-2132.
6. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997, 349:1202-1209. WHO Collaborative Study of Cardiovasular Disease and Steroid Hormone Contraception.
7. Victory R., Diamond M.P. Oral contraceptives and cardiovascular disease: emerging evidence on potential associations with angina, myocardial infarction and stroke. Women Health 2005, 1:133-145.
8. Sondheimer S. Metabolic effects of the birth control pill. Clin Obstet Gynecol 1981, 24:927-941.
9. Porkka K.V., Erkkola R., Taimela S., Raitakari O.T., Dahlen G.H., Viikari J.S. Influence of oral contraceptive use on lipoprotein(a) and other coronary heart disease risk factors. Ann Med 1995, 27:193-198.
10. Sheu W.H., Hsu C.H., Chen Y.S., Jeng C.Y., Fuh M.M. Prospective evaluation of insulin resistance and lipid metabolism in women receiving oral contraceptive. Clin Endocrinol 1994, 40:249-255.
11. Straznicky N., Barrington V.E., Branley P., Louis W.J. A study of interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity, and glucose tolerance in normotensive women. J Hypertens 1998, 16:357-368.
12. Cerel-Suhl S.L., Yeager B.F. Update on oral contraceptive pills. Am Fam Physician 1999, 60:2073-2084.
13. Rimm E.B., Manson J.E., Stampfer M.J., Colditz G.A., Willett W.C., Rosner B., et al. Oral Contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 1992, 35:967-972.
14. Chasan-Taber L., Willett W.C., Stampfer M.J., Hunter D.J., Colditz G.A., Spiegelman D., et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 1997, 20:330-335.
15. Kjos S.L., Peters R.K., Xiang A., Thomas D., Schaefer U., Buchanan T.A. Contraception and the risk of type 2 diabetes mellitus in Latin women with prior gestational diabetes mellitus. JAMA 1998, 280:533-538.
16. Rosenthal A.D., Shu X.O., Jin F., Yang G., Elasy T.A., Li Q., et al. Oral contraceptive use and risk of diabetes among Chinese women. Contraception 2004, 69:251-257.
17. Eriksson A.-K., Ekbom A., Granath F., Hilding A., Efendic S., Östenson C.G. Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabetic Med 2008, 25:834-842.
18. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of WHO consultation. Diabetic Med 1998, 15:539-553.
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
20. Frempong B.A., Ricks M., Sen S., Samner A.E. Effects of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 2008, 93:2097-2103.
21. Godsland I.F. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med 1996, 240(Suppl. 738):1-60.
22. Duffy T.J., Ray R. Oral contraceptive use: a prospective follow-up of women with suspected glucose intolerance. Contraception 1984, 30:197-208.
23. Kim C., Siscovick D.S., Sidney S., Lewis C.E., Kiefe C.I., Koepsell T.D. Oral contraceptive use and association with glucose, insulin and diabetes in young adult women. Diabetes Care 2002, 25:1027-1032.
24. Gaspard U.J., Lefebvre P.J. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 1990, 163:334-343.
25. Godsland I.F., Walton C., Felton C., Proudler A., Patel A., Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992, 74:64-70.
26. Godsland I.F., Crook D., Simpson R., Proudler A., Felton C., Lees B., et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990, 323:1375-1381.